

PATENT ATTORNEY DOCKET NO. 44481-5017-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
)	
Vanitha Ramakrishnan et al.	
Application No.: 09/003,810) Grou	up Art Unit: 1642
Filed: January 7, 1998) Exam	miner: Dr. P. Gambel
For: INHIBITORY IMMUNOGLOBULIN) POLYPEPTIDES TO HUMAN PDGF) BETA RECEPTOR)	RECEIVED
Assistant Commissioner for Patents	
Washington, D.C. 20231	APR 2 3 1998
Sir:	MATRIX CUSTOMER SERVICE CENTER

AMENDMENT TRANSMITTAL FORM

1.	Trans	Transmitted herewith is a Preliminary Amendment				
	[]	Drawings: [] Formal [] Informal (Correction)				
	ĨĨ	Information Disclosure Statement				
	ίí	Form PTO-1449, reference included				
	ίí	Citations				
	ίi	Declaration of Biological Deposit				
	[]	Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino				
		acid sequence.				

3. Extension of Time

The proceedings herein are for a patent application and the provisions of 37 CFR § 1.136(a) apply.

- [x] Applicants believe that no extension of time is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.
- [] Applicants petition for an extension of time, the fees for which are set out in 37 CFR § 1.17(a), for the total number of months checked below:

Total Months Requested	Fee for Extension	[Fee for Small Entity]	
[] one month	\$ 110.00	\$ 55.00	
[] two months	\$ 400.00	\$200.00	
[] three months	\$ 950.00	\$475.00	
[] four months	\$1,510.00	\$755.00	

Extension of time fee due with this request:

If an additional extension of time is required, please consider this a Petition therefor.

- [] An extension for __ months has already been secured and the fee paid therefor of \$___ is deducted from the total fee due for the total months of extension now requested.
- 4. **EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

ATTORNEY DOCKET NO. 44481-5017-03 Application No. 09/003,810 Page 3

5. <u>Fee Calculation</u>

CLAIMS AS AMENDED						
	Claims Remaining After Amendment		Highest No. Previously Paid	Present Extra	at Rate of	Total Fees
Total Claims	24	minus	20	4	x \$22 each=	+\$ 88.00
Independent Claims	3	minus	6	0	x \$82 each=	+\$
[x] First presentation of Multiple dependent claim(s) 1 \$270.00				+ \$270.00		
SUB-TOTAL =						
Reduction by ½ for filing by a small entity - \$179.00						
TOTAL FEE =				\$179.00		

ATTORNEY DOCKET NO. 44481-5017-03 Application No. 09/003,810 Page 4

6.	Fee P	ee Payment		
	[No fee is to be paid at this time.		
[] Check in the amount of \$ which includes, \$ for one month extending and \$ for a claim in excess of twenty claims. The Commissione hereby authorized to charge any additional extension of time fee or additional for claims due to Deposit Account No. 50-0310.				
	[x]	The Commissioner is hereby authorized to charge the additional claims fees in the amount of \$179.00 and other fees which may be required, including fees due under 37 CFR §§ 1.16 and 1.17, or credit any overpayment to Deposit Account 50-0310.		
		Respectfully submitted,		
		MORGAN, LEWIS & BOCKIUS LLP		
		By: Reid G. Adler		
		Reg. No. 30,988		

Dated:April 15, 1998

MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036-5869 202-467-7000



PATENT ATTORNEY DOCKET NO. 44481-5017-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of:)	
Vanit	ha Ramakrishnan et al.)	
Application No.: 09/003,810			Group Art Unit: 1642
Filed: January 7, 1998			Examiner: Dr. P. Gambel
For:	INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR))	
	tant Commissioner for Patents ington, D.C. 20231		
Sir:			

PRELIMINARY AMENDMENT

Prior to the examination on the merits, please amend this application as follows.

04/17/1998 SSAINCERPTAGEOCOTA_616VIS: 09003810

Please cancel claims 1-16 and 18, without prejudice or disclaimer.